The company Acambis prepares a universal vaccine for the treatment of influenza A. Vaccines that are now used attack two virus skin proteins, hemagglutinin and neuramidase, but are easily modified by the virus. Therefore, the vaccine should also change year after year. Acambis' strategy is to attack another protein, the M2 ion channel. All class A viruses have and move very slowly. However, the preparation of the new vaccine is not as simple as the traditional one. He has not yet passed tests with all viruses.